Overview
- CDC data for the two-week period ending June 21 show XFG accounted for 14% of U.S. cases, making it the third-most common strain after NB.1.8.1 and LP.8.1.2.
- The WHO added XFG to its variant under monitoring list on June 25 and assesses its global public health risk as low.
- First sampled in Southeast Asia in January, XFG has been detected in 38 countries and combines mutations from earlier Omicron subvariants F.7 and LP.8.1.2.
- Current evidence shows no increase in disease severity or major symptom differences with XFG compared with prior Omicron strains.
- Approved COVID-19 vaccines are expected to remain effective against XFG, although clinicians have noted hoarseness as an early symptom.